Graeme Clark and the long road to the bionic ear

There is a photograph, widely reproduced in Australian science histories, of Graeme Clark crouching on a beach with a grass stalk pressed to his ear. He was testing a theory — that a tapered tube could guide electrodes of different lengths to different frequency points along the cochlea, the way a hand-rolled leaf might. The image is almost absurdly pastoral for a story that ends with a listed company commanding roughly two-thirds of the global cochlear implant market. But that gap between the pastoral and the industrial is, in many ways, the whole story.

I've been thinking about Clark's trajectory for a while now — not just as a feel-good origin story, but as a case study in what it actually takes to drag a genuinely novel idea from a university lab into a durable commercial product. The hard yards here were not just scientific. They were institutional, political, and financial. And they played out across several decades, with no guarantee of success at any stage.

A personal obsession, rooted in family

Clark has spoken publicly and at length about the motivation behind his work: his father was severely hard of hearing, and the young Graeme watched him struggle with the limitations of conventional hearing aids throughout his childhood. That biographical detail matters more than it might appear. Research programmes as difficult and contested as this one tend to stall without someone willing to absorb years of professional scepticism on the basis of genuine conviction. Clark had that conviction.

After qualifying in medicine and completing a doctorate, Clark joined the University of Melbourne, where he would spend the core of his career. By the late 1960s and into the 1970s, he was pursuing the idea that electrical stimulation of the auditory nerve might produce usable hearing. The idea was not entirely new — researchers in France and the United States had explored single-channel stimulation — but Clark's focus on a multi-channel device, one that could convey some approximation of the frequency complexity of natural hearing, placed him in a small and frequently doubted minority.

Why the sceptics had a point

Let's be honest about what Clark was proposing. He wanted to thread a delicate array of electrodes into the fluid-filled spiral of the cochlea — a structure roughly the size of a pea — without destroying the residual nerve fibres that would carry the electrical signal. He wanted those electrodes to stimulate discrete regions of the cochlea, mimicking the tonotopic organisation by which the ear naturally separates high and low frequencies. And he wanted the resulting signals to be processed and interpreted by the human brain as something recognisable as speech.

Each of those steps had serious objections. The surgery seemed likely to cause additional damage. The electrode array might not survive the biological environment. The brain, many experts argued, could not learn to decode artificially coded electrical input as language. Some researchers and clinicians believed profoundly deaf patients were better served by rehabilitation programmes than by experimental surgery. These were not frivolous concerns. The cochlear implant field had already produced some credibility-damaging episodes internationally, particularly around oversold single-channel devices.

Clark's multi-channel approach required more engineering, more surgery, more signal processing — and therefore carried more ways to fail. The scepticism from parts of the deaf community, who questioned whether deafness was a condition requiring a technological fix at all, added a further layer of complexity that the research team had to navigate thoughtfully and does not deserve to be dismissed.

The University of Melbourne years: building the evidence

Through the 1970s, Clark and his team at the University of Melbourne's Department of Otolaryngology ran systematic animal studies and engineering trials. Funding was scarce and often precarious. The Commonwealth government provided some support through bodies including the National Health and Medical Research Council, but Clark has described periods of genuine uncertainty about whether the programme could continue. He reportedly mortgaged resources — his own included, according to widely-reported accounts — to keep the work going at key moments.

The animal work established that an electrode array could be inserted into the cochlea without necessarily destroying the nerve fibres. The engineering team, which included key collaborators whose contributions Clark has consistently acknowledged, worked on the mechanical design of the array. One of the central problems was that the cochlea narrows as it spirals inward; an array stiff enough to be inserted reliably risked buckling or causing trauma. Clark's beach-grass insight — that a tapered, flexible structure inserted carefully from the wide end could follow the curve — informed the eventual design approach.

By the late 1970s, the team was ready to attempt the procedure in a human patient. The first implantation under Clark's programme took place in the late 1970s at the Royal Victorian Eye and Ear Hospital in East Melbourne. Rod Saunders, the patient, was profoundly deaf following illness and became the subject of extensive testing over subsequent years. The results, carefully documented and published in peer-reviewed literature, showed that a multi-channel device could deliver meaningful speech perception — not perfect hearing, but something genuinely functional that a single-channel device could not match.

From the lab to a company: the Nucleus device

Scientific proof of concept is not a product. Turning Clark's work into something manufacturable and commercially viable required a partner with engineering and regulatory capability. That partner was Nucleus, a subsidiary of the Australian industrial conglomerate Nucleus Limited, which itself had roots in the Pacific Dunlop group. The collaboration between the University of Melbourne research team and what became Cochlear Pty Ltd produced the Nucleus cochlear implant system — a behind-the-ear speech processor paired with the implanted electrode array.

For more on how that commercial structure developed and eventually produced the listed company, the full account is in How Cochlear Built A Global Empire. The short version: the path from university lab to regulated medical device required US Food and Drug Administration approval, which the Nucleus device received in the mid-1980s — a regulatory milestone that opened the American market and effectively validated the technology internationally. Clark's team provided the clinical and scientific evidence base that underpinned those regulatory submissions.

Recognition, and a fair reckoning

Clark received the Australia Prize in the early 1990s, was made a Companion of the Order of Australia, and was awarded numerous international honours. The University of Melbourne's Graeme Clark Institute for Biomedical Engineering, established in the 2010s, carries his name. He was knighted — Sir Graeme Clark — and the technology he developed is widely cited as one of the most successful Australian scientific exports of the twentieth century.

I'll admit I find the hagiographic version of this story slightly unsatisfying, not because Clark's contribution was overstated, but because flattening it into a lone-genius narrative obscures what actually happened. The electrode engineering work, the signal processing, the surgical technique refinements, the clinical assessment protocols — these involved substantial teams. Jim Patrick, who joined the commercial development side and became a long-serving figure at Cochlear, is one of many whose contributions to the engineering are well-documented. Clark himself has been consistent in acknowledging this. The myth of the solitary inventor tends to make the work seem more miraculous and less replicable than it actually was.

What Clark did do — and this is genuinely hard to do — was sustain a research programme across decades of resource constraint and professional scepticism, publish the kind of rigorous evidence that could withstand regulatory and clinical scrutiny, and work constructively with commercial partners without losing the scientific standards that made the evidence base credible. That combination is rarer than the grant applications suggest.

What the cochlear implant story tells us about Australian research commercialisation

The cochlear implant is sometimes cited as a template for Australian research commercialisation. I'd be careful with that reading. It succeeded in part because Clark had a sufficiently long runway at a single institution to develop the evidence base properly — something harder to replicate in an era of short-term grant cycles and increasing pressure on universities to produce commercial outcomes quickly. It also benefited from a manufacturing partner willing to make a long-term bet on an uncertain technology, at a time when Australian industry had somewhat more appetite for that kind of commitment than it arguably does now.

The global business that grew from Clark's research — now Cochlear Limited, listed on the ASX and consistently one of Australia's most valuable medical technology companies — is examined in depth in Cochlear Global Hearing Implant Dominance. For our purposes here, the research story is itself the point. The product didn't emerge from a pitch deck. It emerged from a scientist who was convinced enough to keep going when most of his peers thought the idea wouldn't work, and careful enough to generate evidence that eventually proved them wrong.

That is, for those of us watching Australian companies try to build durable global positions from genuinely novel science, still the most instructive version of the story. See the fuller picture over at the Outliers & Global Empires hub.

— Priya Naidu, Outliers & Global Champions